Alterity Therapeutics Issues 4,105 Ordinary Shares Following Option Exercise at $0.50 Each

Exercise of ATHO Options at $0.50 on 1 July 2026

On 1 July 2026, Alterity Therapeutics filed an Appendix 2A for quotation of securities, reporting that 4,105 options from the ATHO series were exercised and converted into fully paid ordinary shares the same day. Each option was exercised at AUD $0.50, resulting in gross proceeds of $2,052.50 for Alterity. The company did not provide further details regarding the option holders or strategic context in this update.

The new shares were issued as part of an existing quoted class, granting full voting and economic rights equivalent to all other ATH ordinary shares from the Date of Issue. These securities were not issued under an employee incentive plan. The application confirms that the shares are to be quoted on the ASX and will rank equally with existing ordinary Share Capital from 1 July 2026.

Total Ordinary Shares Increase to 217,512,967

Following quotation of the 4,105 new shares, Alterity Therapeutics’ total quoted fully paid ordinary shares stand at 217,512,967. Although this issuance is small relative to the overall capital base, the update provides a current snapshot of Alterity’s securities as of 1 July 2026. This figure is generated by ASX systems and may not reflect other pending filings such as Appendix 2A, 3G, or 3H forms.

Besides ordinary shares, two quoted option series remain outstanding: 18,620,624 ATHO options expiring 31 August 2026, and 24,446,043 ATHOA options expiring 26 February 2027. These options represent potential dilution if exercised before expiry and are important for investors tracking the company’s capital structure.

18.6 Million ATHO Options Outstanding Ahead of 31 August 2026 Expiry

The ATHO series is set to expire on 31 August 2026, with 18,620,624 options still unexercised. The decisions by holders to exercise these options at $0.50 or allow them to lapse will influence Alterity’s share count and cash inflows. Exercising the options could provide significant additional capital, while expiry without exercise would avoid dilution.

Holder choices will likely depend on factors such as the Market Price of ATH shares relative to the exercise price, overall sentiment toward clinical-stage biotech firms, and any corporate announcements before the expiry. The company did not provide guidance on expected exercise activity in this update.

24.4 Million ATHOA Options Expiring February 2027

In addition to the ATHO series, Alterity has 24,446,043 ATHOA options quoted on the ASX, expiring on 26 February 2027. This series extends potential option exercises and related share issuances into 2027. The exercise price and other terms of the ATHOA series were not restated in this update; interested investors should consult prior company disclosures for details.

The coexistence of two quoted option series alongside numerous unquoted options highlights the complexity of Alterity’s capital structure. Shareholders should monitor how these series and their exercise prices compare to the ATH share price to assess dilution risk over the next 12 to 18 months.

Broad Range of Unquoted Options Reflects Company’s Incentive and Financing History

The update also outlines Alterity’s unquoted options, spanning fifteen series with expiry dates from November 2026 through June 2031 and exercise prices in both AUD and USD. AUD-denominated exercise prices range from $0.20 (ATHAA, expiring March 2029) to $1.875 (ATHAAE, expiring November 2026), while USD-denominated options range from USD $0.155 (ATHAB, expiring March 2029) to USD $0.43 (ATHAF, expiring August 2030).

The largest unquoted option series by volume is ATHAF, with 6,248,004 options expiring 8 August 2030 at USD $0.43, followed by ATHAJ with 4,245,000 options expiring 15 April 2031 at USD $0.302, and ATHAL with 3,000,000 options expiring 15 June 2031 at AUD $1.00. The presence of USD-denominated options aligns with Alterity’s history of capital raising and Investor relations activity in the U.S., where it previously listed American Depositary Receipts. The company did not disclose details about holders of these unquoted options.

Cash Proceeds and Implications of Option Exercise

The gross proceeds from exercising 4,105 ATHO options on 1 July 2026, at AUD $0.50 each, total $2,052.50. Although this amount is minor for a listed biotech and unlikely to significantly impact Alterity’s cash reserves or operational runway, it indicates at least one option holder deemed early exercise worthwhile. The company did not reveal the identity of the exercising party or provide updates on cash position or runway in this release.

Exercise activity near the start of the final two-month window before option expiry can sometimes signal holder expectations about the share price. However, conclusions drawn from this single small exercise are limited, and no clear share price impact was evident from public data.

New Shares Fully Rank With Existing Ordinary Shares

The Appendix 2A filing confirms the 4,105 newly issued shares rank equally in all respects with existing fully paid ordinary shares from 1 July 2026. This grants holders identical voting, dividend, and participation rights. No escrow or secondary ranking applies, as these shares were converted into an existing quoted class.

This equal ranking complies with ASX Listing Rules and standard practice for shares issued via option exercise in Australia. Existing shareholders can expect these shares to participate equally in future corporate actions, capital distributions, or entitlement offers.

Overview of Alterity’s Capital Structure and Key Expiry Dates

This update offers a consolidated view of Alterity Therapeutics’ securities as of 1 July 2026. The company has 217,512,967 quoted ordinary shares, two quoted option series (ATHO and ATHOA), and fifteen unquoted option series with expiries ranging from November 2026 to June 2031. This layered structure means investors should monitor multiple potential dilution events as option expiry dates approach and holders decide whether to exercise.

The most imminent date is the 31 August 2026 expiry of the ATHO series, with 18,620,624 options outstanding. The outcome of this expiry—whether full, partial exercise, or lapse—will have a more significant impact on Alterity’s share count and cash inflows than the recent small conversion. Investors and analysts should watch for further Appendix 2A filings indicating additional ATHO exercises ahead of the deadline.

Significance of This Routine Securities Filing for Investors

While the exercise of 4,105 options is a minor administrative event, the filing fulfills an important transparency requirement under ASX Listing Rules. Appendix 2A applications ensure new securities are properly quoted and provide the market with an accurate, current view of total securities on issue. Such disclosures are essential for both retail and institutional investors tracking capital management.

As a clinical-stage biopharmaceutical company, Alterity’s share price and investor interest are primarily influenced by clinical trial results, regulatory news, and financing developments rather than small option exercises. Investors focused on the company’s Business should await future updates on its therapeutic pipeline for more significant catalysts. No operational or clinical updates accompanied this filing, and no immediate share price impact was evident from available public information.